Opus Genetics, Inc.
About Opus Genetics, Inc.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $14.2M
- Net income
- -$49.6M
- Total assets
- $50.2M
- Market cap
- $328.0M
- Operating margin
- -271.9%
- Net margin
- -349.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $14.2M
- Operating expenses
- $52.8M
- Operating income
- -$38.6M
- Income tax
- $0
- Net income
- -$49.6M
- EPS (basic)
- $-0.80
- EPS (diluted)
- $-0.80
Balance sheet
- Total assets
- $50.2M
- Current assets
- $50.0M
- Total liabilities
- $34.9M
- Current liabilities
- $7.8M
- Shareholders’ equity
- $15.3M
Cash flow
- Operating cash flow
- -$35.3M
- Investing cash flow
- -$14.8M
- Financing cash flow
- $50.0M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
- Market cap
- $328.0M
- EPS (diluted)
- $-0.8
- Shares outstanding
- 81.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 6, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $49.6M in FY2025.
- Revenue grew 29% from FY2024 to FY2025.
- Trading 30% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Opus Genetics, Inc..
Write a review
News about Opus Genetics, Inc.
News & sentiment via Polygon.io
